Read More Pharma Industry News Amgen and UCB resubmit BLA for EVENITY to transform osteoporosis treatment in postmenopausal women Amgen, in collaboration with UCB, has announced the resubmission of the biologics license application (BLA) for their osteoporosis… bypharmanewsdailyJuly 15, 2018
